Skip to main content

Fiscal Wizard · Single-issue tearsheet

BNTX / Jun 21, 2026 Run #7444

BNTX

BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Composite verdict

F 24.8 / 100
Bearish setup · Mean Reversion 11 drivers · 3 gates blocking
  • Connors RSI(2)
  • Star
  • Double 7s
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 213th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 15Mean-reversion Bearish 36

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -38%
Asset value $76.02Earnings power value $7.05Price $90.89

Priced above its no-growth earnings power value ($7.05/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

49.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Free Cash Flow Yield 0
Return on Assets 81
Days Sales Outstanding 0
Return on Capital Employed 80
Margin of Safety 3

Technicals Bearish

0.1 / 100

Bearish setup leads (Connors RSI(2), Star, Double 7s); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Connors RSI(2) 17
Double 7s 18
Vortex Signal 19

Risk Gates

3 blocking 4 caution

3 guards active, 20 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BNTX.